Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.49 |
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | MPC2 | O95563 | 2/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ESRRA | P11474 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935594 | 0.86 | PPARG (0.73) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL6358465 | 0.85 | PPARG (0.71) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL5935582 | 0.85 | PPARG (0.74) | PPARGFFAR1PPARAMPC2CYP2C8 | |
| SCHEMBL6358469 | 0.85 | PPARG (0.71) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL6359266 | 0.84 | PPARG (0.73) | PPARGFFAR1PPARAMPC2CYP2C8 | |
| SCHEMBL6359264 | 0.84 | PPARG (0.73) | PPARGFFAR1PPARAMPC2CYP2C8 | |
| SCHEMBL7797534 | 0.83 | PPARG (0.62) | PPARGFFAR1PPARAMPC2CYP2C8 | |
| SCHEMBL5935615 | 0.79 | PPARG (0.54) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL5935648 | 0.78 | PPARG (0.60) | PPARGFFAR1PPARACYP3A4RXRA | |
| Hydrochloric Acid SCHEMBL5935818 | 0.77 | PPARG (0.59) | PPARGFFAR1PPARACYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0958296-B1 | HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | REDDYS LAB LTD DR (IN) | 2003-07-30 | — | — | EP | claimed |
| US-6573268-B1 | Administering novel azolidinedione derivatives, tautomers, stereoisomers, polymorphs, pharmaceutically acceptable salts and solvates to treat diabetes | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-06-03 | — | — | US | claimed |
| US-20020123502-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. | 2002-09-05 | — | — | US | claimed |
| US-6372750-B2 | COMPOUNDS SUCH AS 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL)ETHOXY)PHENYL METHYL)THIZOLIDINE-2,4-DIONE MADE BY CYCLIZATION, CHEMICAL REDUCTION, HYDROLYSIS, AZOLIDINEDIONE DERIVATIVES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-04-16 | — | — | US | claimed |
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2001-10-18 | — | — | US | claimed |
| US-RE39266-E1 | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S LABORATORIES, LIMITED (IN) | 2006-09-05 | — | — | US | disclosed |
| US-20050032864-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S LABORATORIES LIMITED | 2005-02-10 | — | — | US | disclosed |
| US-6780992-B2 | 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL) -ETHOXY)PHENYL METHYL)THIAZOLIDINE-2,4-DIONE FOR EXAMPLE; ALSO OXAZOLIDINE-2,4-DIONE, AND 1,2,4-OXADIAZOLIDINE-3,5-DIONE DERIVATIVES; REDUCING BLOOD GLUCOSE LEVELS | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-08-24 | — | — | US | disclosed |
| EP-0958296-B1 | HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | REDDYS LAB LTD DR (IN) | 2003-07-30 | — | — | EP | disclosed |
| US-6573268-B1 | Administering novel azolidinedione derivatives, tautomers, stereoisomers, polymorphs, pharmaceutically acceptable salts and solvates to treat diabetes | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-06-03 | — | — | US | disclosed |
| US-20020123502-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. | 2002-09-05 | — | — | US | disclosed |
| US-6372750-B2 | COMPOUNDS SUCH AS 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL)ETHOXY)PHENYL METHYL)THIZOLIDINE-2,4-DIONE MADE BY CYCLIZATION, CHEMICAL REDUCTION, HYDROLYSIS, AZOLIDINEDIONE DERIVATIVES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-04-16 | — | — | US | disclosed |
| US-6310069-B1 | INTERMEDIATES TO AZOLIDINEDIONE ANTIDIABETIC COMPOUNDS SUCH AS 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL)ETHOXY)PHENYL METHYL)THIAZOLIDINE-2,4-DIONES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-10-30 | — | — | US | disclosed |
| US-6114526-A | REACTING AN AMINO DERIVATIVE WITH A HETEROCYCLIC DIONE COMPOUND TO FORM AN ANTIDIABETIC AGENT | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-09-05 | — | — | US | disclosed |
| US-5985884-A | TREATMENT AND/OR PROPHYLAXIS OF DISEASES OR CONDITIONS IN WHICH INSULIN RESISTANCE IS THE UNDERLYING PATHOPHYSIOLOGICAL MECHANISM SUCH AS TYPE II DIABETES, IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDAEMIA, HYPERTENSION, CORONARY HEART DISEASE | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032864-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B2 | PPARG 380/4885FFAR1 1350/4885PPARA 664/4885 |
| US-20020123502-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B1 | PPARG 443/4885FFAR1 1148/4885PPARA 769/4885 |
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B1 | PPARG 380/4885FFAR1 1277/4885PPARA 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.